-

01:25:54 AM

ADXS Stock News

ADXS - Advaxis, Inc.

06/05/23 8:00 AM

OTC : ADXS

clinical triallow float

Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., June 05, 2023

RHEA-AI

neutral

05/25/23 5:05 PM

OTC : ADXS

clinical triallow float

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose) Tumor response, volume and T2 signal reduction were observed earlier in the 1.2 mg once daily group, with deeper and

RHEA-AI

neutral

05/23/23 1:20 PM

OTC : ADXS

earningslow float

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial results and provided a corporate update. “Our immediate priority is to complete enrollment in

RHEA-AI

neutral

04/27/23 8:00 AM

OTC : ADXS

low float

Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it will

RHEA-AI

neutral

03/03/23 8:00 AM

OTC : ADXS

clinical triallow float

Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee

Ayala Pharmaceuticals, Inc.

RHEA-AI

neutral

02/10/23 7:00 AM

OTC : ADXS

earningslow float

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October

RHEA-AI

positive

01/19/23 9:37 AM

OTC : ADXS, ADXSD

acquisitionlow float

Advaxis and Ayala Pharmaceuticals Complete Merger

Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria

RHEA-AI

neutral

01/12/23 8:04 AM

OTC : ADXS, ADXSD

clinical triallow float

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reported Four out of six patients treated are still on study and PSA values are being followed up MONMOUTH JUNCTION, N.J.,

RHEA-AI

neutral

10/19/22 6:30 AM

OTC : ADXS, ADXSD

acquisitionlow float

Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62 .5% and 37 .5 %

RHEA-AI

positive

09/12/22 6:40 PM

OTC : ADXS, ADXSD

earningslow float

Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update

RHEA-AI

neutral

1 2 3 4 5 6 Next

ADXS Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.advaxis.com
CeoKenneth Berlin
Security nameAdvaxis, Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees15
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address305 College Rd E
StateNew Jersey
CityPrinceton
Zip08540-6608
CountryUS
Phone17325451590

About Advaxis, Inc.

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.